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Thepresentstudieswerefocusedontheformationandcharacterizationofstericallystabilizedarchaeosomesmadefromasynthetic
PEGylatedarchaeal lipid.Inaﬁrststep,asyntheticarchaealtetraetherbipolarlipidwasfunctionalizedwithapoly(ethyleneglycol),
PEG, and (PEG45-Tetraether) with the aim of coating the archaeosome surface with a sterically stabilizing hydrophilic polymer.
In a second step, Egg-PC/PEG45-Tetraether (90/10wt%) archaeosomes were prepared, and their physicochemical characteristics
were determined by dynamic light scattering (size, polydispersity), cryo-TEM (morphology), and by high-performance thin layer
chromatography (lipid composition), in comparison with standard Egg-PC/PEG45-DSPE formulations. Further, a ﬂuorescent dye,
the carboxyﬂuorescein, was encapsulated into the prepared archaeosomes in order to evaluate the potential of such nanostructures
as drug carriers. Release studies have shown that the stability of Egg-PC/PEG45-Tetraether-based archaeosomes is signiﬁcantly
higher at 37◦C than the one of Egg-PC/PEG45-DSPE-based liposomes, as evidenced by the slower release of the dye encapsulated
into PEGylated archaeosomes. This enhanced stability could be related to the membrane spanning properties of the archaeal
bipolar lipid as already described with natural or synthetic tetraether lipids.
1.Introduction
In the drug-delivery ﬁeld, several nanocarriers have been
proposed to improve the therapeutic index of various
biologicallyactivemoleculessuchaspeptides.Indeed,invivo
administration of peptides is still limited by their poor
bioavailability and susceptibility to cleavage by proteases.
In order to obtain a satisfactory therapeutic eﬀect, the
peptide has to be frequently administrated at high doses
leading to unwanted toxic eﬀects, such as induction of
immune response. Consequently, peptide encapsulation into
site-speciﬁc delivery systems can oﬀer solutions to the
above-mentioned problems. Indeed, the nanocarriers can (i)
enhance drug solubility, (ii) control drug release thus avoid-
ing toxic side eﬀects, (iii) improve drug biodistribution, (iv)
and, if appropriate molecule is grafted on the nanocarrier
surface, target a speciﬁc site of action. Several nanovectors
have been used to encapsulate various therapeutic peptides
such as liposomes, nanoparticles, and nano- or microgels
[1–8]. Among these nanocarriers, liposomes are of great
importance because of their relatively large carrying capacity
andthepossibilitytoentrapeitherhydrophilic,hydrophobic,
or amphiphilic drugs. Moreover, a good knowledge of such
vectors has been acquired since the ﬁrst discovery of lipo-
somes by Bangham and Horne [9] attested by commercially
available anticancer liposomial formulations such as Doxil
[10, 11]. However, despite encouraging results, a major
limitation to the development of liposomes as drug carriers
is their instability, especially during their transit to the site
of action [12]. Attempts to improve their stability, either by
incorporation of high amount of cholesterol or by coating
the liposome surface with poly(ethylene glycol), have led to
limited success.
Within this context, archaeosomes, made with one or
more of either the ether lipids found in Archaea bacteria
or synthetic archaeal lipids, constitute a novel family of2 Journal of Drug Delivery
liposomes exhibiting higher stabilities in several conditions,
such as high temperature, alkaline or acidic pH, presence
of phospholipases, bile salts, and serum media [13, 14].
Therefore, because of their biocompatibility and higher
stability, archaeosomes have been extensively studied for
potential applications as drug/gene and vaccine delivery
systems [14, 15].
Over the last decade, our research group has developed
synthetic analogues of natural archaeal tetraether lipids and
studied their uses in cationic archaeosome formulations as
eﬃcient gene delivery systems [16–18]. Our next objective
was to evaluate the potential applications of archaeosome
technology for the delivery of additional hydrophilic sub-
strates such as antitumoral peptides (Project Sealacian:
encapsulation of natural marine peptides, extracted from
Scyliorhinus canicula, for their site-speciﬁc delivery). Our
attention was then directed towards the preparation and the
formulation of a PEGylated archaeal tetraether lipid (PEG45-
Tetraether) to provide neutral coated archaeosomes valuable
as peptide nanocarriers. In order to assess the value of this
new family of stealth liposomes, physicochemical charac-
teristics (DLS, cryo-TEM, and HPTLC), dye encapsulation
and release proﬁle for a PEGylated archaeosome formulation
were determined and compared to those measured from a
conventional PEGylated liposome formulation.
2.MaterialsandMethods
2.1. Materials. Egg-PC was purchased from Sigma. 1,2-
distearoyl-sn-glycero-3-phosphatidylethanolamine-N-
[methoxy-poly(ethylene glycol)-2000], ammonium salt,
(PEG45-DSPE) was purchased from Aventi Polar. PEG45-
Tetraether was synthesized according to a four-step pro-
cedure from the tetraether diol 1 available in our labora-
tory [13]. All reactions were carried out under nitrogen
atmosphere with dry, freshly distilled solvents under anhy-
drous conditions. Dichloromethane (CH2Cl2) and methanol
(MeOH) were distilled over calcium hydride. All other
reagents were used directly from the supplier without further
puriﬁcationunlessnoted.Analyticalthin-layerchromatogra-
phy (TLC) was performed on Merck 60 F254 silica gel nonac-
tivatedplates.Asolutionof5%H2SO4 inEtOHorultraviolet
ﬂuorescence was used to develop the plates. Column chro-
matography was performed on silica gel MERCK 60 H (5–
40μm). Nuclear magnetic resonance spectra (1HN M Ra n d
13C NMR) were recorded on a Brucker ARX 400 instrument
(1Ha t4 0 0 M H z ,13C at 100MHz). Data are reported as
follows: chemical shift (number of hydrogen, multiplicity,
and coupling constants if applicable). The chemical shifts
(δ) are reported as parts per million (ppm) referenced to
the appropriate residual solvent peak. Coupling constants
are reported in Hertz (Hz). Abbreviations are as follows: s
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of
doublet), and m (multiplet). High-resolution mass spectra
(HRMS) were performed by CRMPO (Universit´ ed eR e n n e s
1) on a MS/MS ZabSpec TOF Micromass. Accurate masses
are reported for the molecular ions [M+H]+,[ M + N a ] +,
[M+K]+,o r[ M −H]−. Optical rotations were measured on
a Perkin-Elmer 341 polarimeter. IR spectra were recorded on
a Nicolet 250 FT-IR spectrometer.
HPTLC plates (20∗10cm, silica gel 60, 0.2mm layer
thickness, Nano-Adamant UV254)w e r ep u r c h a s e df r o m
Macherey-Nagel. Before use, the HPTLC plates were pre-
washed with methanol, dried on a CAMAG TLC plate heater
III at 120◦Cf o r2 0m i n ,a n dk e p ti na na l u m i n u mf o i li na
desiccator at room temperature. All solvents were of HPTLC
grade.
2.2. Synthesis of PEG45-Tetraether
1-O-acetyl-2,2 -di-O-(3,7,11,15-tetramethylhexadecyl)-3,3 -
O-(1,32-(13,20-dioxa)-dotriacontane-(cis-15,18-methylid-
en))diyl-di-sn-glycerol 2. A mixture of tetraether diol 1
(600mg, 0.495mmol, 1equiv.), acetic anhydride (151μL,
3.5equiv .)andsodiumacetate(41mg,1equiv .)wasstirred
under reﬂux for 24h. Water was added and the aqueous
phase was extracted twice with CH2Cl2. The combined
organic phases were dried (MgSO4) and concentrated under
reduced pressure. The residue was puriﬁed by ﬂash chro-
matography on silica gel (petroleum ether (PE)/AcOEt:
98:2) to yield the monoacetate derivative 2 (305mg, 49%)
as a colorless oil. Rf = 0.15 (PE/AcOEt: 9:1). [α]
20
D :+ 9 ◦
(c 1.0, CHCl3). FT-IR υ (cm−1) 2924 (CH3), 2853 (CH2),
1746 (CO), 1463 (CH2), 1377 (CH3), 1115 (COC); 1HNMR
(CDCl3, 400MHz) δ 0.80–0.89 (31H, m), 1.02–1.81 (92H,
m), 1.91–1.98 (1H, m), 2.07 (3H, s), 2.13–2.23 (2H, m), 3.29
(4H, d, J = 6.9Hz), 3.39 (4H, t, J = 6.7Hz), 3.43 (4H,
t, J = 6.6Hz), 3.44–3.74 (m, 8H), 4.11 (1H, dd, J = 5.7,
11.6Hz), 4.22 (1H, dd, J = 4.1, 11.6). 13CN M R( C D C l 3,
100MHz) δ 19.61, 19.68, 19.75, 20.93, 22.63, 22.72, 24.32,
24.46, 24.48, 24.81, 26.13, 28.02, 29.53, 29.62, 29.71, 29.79,
30.03, 31.61, 32.81, 33.01, 36.73, 37.22, 37.33, 37.38, 37.43,
37.51, 38.79, 39.38, 40.12, 40.68, 63.12, 64.13, 68.61, 68.89,
68.91, 70.16, 70.19, 70.6, 70.9, 71.7, 71.9, 75.6, 76.5, 78.6,
170.9.HRMS(ESI)calcd.forC79H157O9 (M+H)+ 1250.1827,
found 1250.1823; HRMS (ESI) calcd. for C79H156O9Na
[M+Na]+ 1272.1647, found 1272.1650; HRMS (ESI) calcd.
for C79H156O9K [M+K]+ 1288.1386, found 1288.1381.
1-O-acetyl-1 -carboxy-2,2 -di-O-(3,7,11,15-tetramethylhex-
adecyl)-3,3 -O-(1,32-(13,20-dioxa)-dotriacontane-(cis-15,
18-methyliden))-diyl-di-sn-glycerol 3. To a solution of alco-
hol 2 (50mg,0.04mmol,1equiv .)inAcOEt(1mL),a0.5M
aqueous solution of KBr (8μL, 0.1equiv.) and TEMPO
( 1m g,0 . 2e q u i v . )w e r ea d d e d .A t0 ◦C ,a5 %a q u e o u ss o l u t i o n
of NaOCl (69μL) was then added dropwise. The reaction
mixture was stirred at room temperature for 2h, the solution
was acidiﬁed until pH 3-4 using 5% HCl and a 25% aqueous
solution of NaO2Cl (17μL) was added slowly. After stirring
f o r3ha tr o o mt e m p e r a t u r e ,t h em i x t u r ew a se x t r a c t e dw i t h
AcOEt, washed with a saturated aqueous solution of NaCl,
dried (MgSO4), and concentrated under reduced pressure
to give the carboxylic acid derivative 3 (45mg, 90%) as
a colorless oil. Rf = 0.28 (CH2Cl2/CH3OH: 9:1). FT-IR
υ (cm−1) 2924 (CH3), 2853 (CH2), 1746 (COCH3), 1733
(COOH), 1463 (CH2), 1377 (CH3), 1115 (COC); 1HNMRJournal of Drug Delivery 3
(CDCl3, 400MHz) δ 0.80–0.89 (31H, m), 1.02–1.81 (92H,
m), 1.91–1.98 (1H, m), 2.07 (3H, s), 2.13–2.23 (2H, m), 3.29
(4H, d, J = 6.9Hz), 3.39 (4H, t, J = 6.7Hz), 3.41–3.72 (m,
12H), 3.79 (1H, ddd, J=1.0, 3.3, 10.5Hz), 4.03 (1H, dd,
J = 4.1, 11.6Hz), 4.11 (1H, d, J = 5.7, 11.6Hz), 4.22 (1H,
dd, J = 4.1, 11.6Hz). 13CN M R( C D C l 3, 100MHz) δ 19.61,
19.68, 19.75, 20.91, 22.63, 22.72, 24.3, 24.46, 24.48, 24.81,
26.11, 28.02, 28.79, 29.51, 29.62, 29.73, 29.82, 30.02, 31.59,
32.82, 33.01, 36.68, 36.81, 36.93, 37.04, 37.12, 37.19, 37.33,
37.38, 37.41, 37.52, 38.84, 39.37, 40.12, 40.66 63.08, 63.12,
64.15, 68.65, 68.89, 68.91, 70.16, 70.19, 70.63, 70.91, 71.72,
71.91, 75.57, 76.53, 78.59, 170.91, 171.88. HRMS(ESI) calcd.
for C79H153O10 [M−H]− 1262.1463, found 1262.1447.
PEG45-Tetraether. To a solution of carboxylic acid 3
(16.6mg, 0.015mmol, 1equiv.) and TBTU (4.6mg, 1equiv.)
in dry CH2Cl2 (1mL) was added DIEA (3.4μL, 1.3equiv.)
under a nitrogen atmosphere. After 20min at room temper-
ature, a solution of H2N-PEG45-OMe 4 (24.4mg,1equiv .)
in dry CH2Cl2 (2mL) was added and the reaction mixture
was stirred under reﬂux for 12h. A few drops of a 5%
HCl aqueous solution were then added and the solvents
were removed under reduced pressure. The residue was
dissolved in CHCl3 (1mL) and puriﬁed on a Sephadex
LH-20 column eluting with a mixture of CHCl3/CH3OH
(9:1) to give a white solid (41mg, 80%) composed of the
expected monoacetate derivative 5 and the starting H2N-
PEG45-OMe 4 in a 80:20 ratio. FT-IR υ (cm−1) 2924 (CH3),
2855 (CH2), 1746 (COCH3), 1651 (CONH), 1103 (COC);
1HN M R( C D C l 3, 400MHz) δ 0.82–0.86 (31H, m, 10CH3),
1.00–1.80 (92H, m), 1.91–1.98 (1H, m), 2.06 (3H, s), 2.13–
2.23 (2H, m), 3.27 (4H, d, J=6.9Hz), 3.36–3.58 (23H, m),
3.37 (3H, s), 3.59–3.68 (169H, m), 3.73–3.77 (1H, m), 3.81
(1H, dd, J=4.1, 5.6Hz), 3.88 (1H, dd, J=2.5, 6Hz), 4.08
(1H, dd, J=5.6, 11.6Hz), 4.21 (1H, dd, J=4.1, 11.6Hz),
7.03 (1H, m). 13CN M R( C D C l 3, 100MHz) δ 14.08, 19.58,
19.65, 19.72, 20.91, 22.60, 22.69, 24.32, 24.45, 24.77, 26.03,
26.07, 26.15, 27.93, 28.82, 29.32–29.84, 32.76, 33.9, 36.84–
37.50, 38.57, 39.33, 39.70 59.00, 62.97, 68.60, 69.74, 69.83,
70.29, 70,53, 70.91, 71.53, 71.56, 71.69, 71.83, 71.89, 75.60,
77.20, 78.21, 80.50, 170.53, 170.72. To a solution of this
white solid (41mg) in a CH2Cl2/CH3OH (1:1) mixture, was
added a freshly prepared solution of CH3ONa in CH3OH
(0.1M, 1equiv.). The reaction mixture was stirred at room
temperature for 4h. Amberlite resin (IR120) was added,
the reaction mixture was ﬁltered, and the solvents were
evaporated under reduced pressure. A white powder was
isolated (41mg) composed of the desired PEG45-Tetraether
and the starting H2N-PEG45-OMe 4 in a 80:20 ratio. Rf
= 0.28 (CHCl3/CH3OH/H2O: 9:1). FT-IR υ (cm−1) 2927
(CH3), 2855 (CH2), 1652 (CONH), 1103 (COC); 1HN M R
(CDCl3, 400MHz) δ 0.82–0.86 (31H, m, 10CH3), 1.00–1.80
(92H, m), 1.91–1.98 (1H, m), 2.13–2.23 (2H, m), 3.27 (4H,
d, J = 6.9Hz), 3.36–3.58 (23H, m), 3.37 (3H, s), 3.59–3.68
(169H, m), 3.73–3.77 (1H, m), 3.81 (1H, dd, J = 4.1, 5.6Hz),
3.88 (1H, dd, J = 2.5, 6Hz), 7.03 (1H, m). 13C NMR (CDCl3,
100MHz) δ 14.09, 19.58, 19.65, 19.72, 22.60, 22.69, 24.32,
24.45, 24.77, 26.03, 26.07, 26.15, 27.93, 28.82, 29.32–29.84,
32.76, 33.9, 36.84–37.50, 38.57, 39.33, 39.70 59.00, 62.97,
68.60, 69.74, 69.83, 70.29, 70,53, 70.91, 71.53, 71.56, 71.69,
71.83, 71.89, 75.60, 77.20, 78.21, 80.50, 170.52.
2.3. Preparation of PEGylated Archaeosomes and PEGy-
lated Liposomes. Stock solutions of Egg-PC (1mg/mL) and
PEG45-DSPE (1mg/mL) were prepared in CHCl3 :CH 3OH
(2:1, v/v), while stock solutions of PEG45-Tetraether
(1mg/mL) were prepared in CHCl3.
Liposomes and archaeosomes were obtained by the
hydration method as already described elsewhere [16–18].
Brieﬂy, the selected lipid solutions were mixed to yield either
a mixture of Egg-PC and PEG45-DSPE (90:10wt%) or a
mixture of Egg-PC and PEG45-Tetraether (90:10wt%) with
a total lipid concentration of 1mg/mL. The organic solvents
were then evaporated using a rotary evaporator, and the
lipid ﬁlms thus obtained were dried under high vacuum for
2 hours at room temperature. The dried lipid ﬁlms were
then hydrated with 1mL of milliQ water. The solutions were
v ortex edandleftat4 ◦Covernight.Archaeosomeorliposome
formulations were sonicated at room temperature for two
times 5min with interval of 5min using a Fischer scientiﬁc
sonication bath (FB 15051) at 80KHz. Each formulation was
realized in duplicate.
2.4. Encapsulation of Carboxyﬂuorescein into PEGylated Ar-
chaeosomes. PEG45-Tetraether (90:10wt%) based archaeo-
somes and Egg-PC/PEG45-DSPE (90:10wt) PEGylated Li-
posomes: Carboxyﬂuorescein (CF) was encapsulated in
Egg-PC based liposomes during the hydration phase as
described elsewhere [19]. Brieﬂy, Egg-PC/PEG45-Tetraether
(90:10wt%) and Egg-PC/PEG45-DSPE (90:1wt%) lipid
ﬁlms were prepared as described above. After drying, both
lipid ﬁlms were hydrated with 1mL of a tris(hydroxyl
methyl) methylamine buﬀer (Tris buﬀer) at pH 7.4 con-
taining CF at a concentration of 100mM. The solutions
w e r ev o r t e x e da n dl e f ta t4 ◦C overnight. Both PEGylated
archaeosomes and PEGylated liposomes containing CF were
sonicated (Fischer scientiﬁc sonication bath FB 15051-
80KHz) at room temperature for two times 5min with
intervalof5min.NonencapsulatedCFwaseliminatedbysize
exclusion column chromatography on the Sephadex G-50gel
with the Tris buﬀer as eluent. Both PEGylated archaeosomes
and PEGylated liposomes containing CF were analyzed by
DLS and by ﬂuorescence using a Fluoromax-3 (Horiba)
spectroﬂuorimeter with excitation and emission wavelengths
of 490 and 515nm, respectively.
2.5. Size, Polydispersity, and Zeta Potential Measurements.
The size (average diameter obtained by the cumulant result
method), polydispersity and zeta potential of the formu-
lations were measured by dynamic light scattering using
a Delsa Nano Beckman Coulter apparatus at 25◦C. The
samples were diluted 2 times with milliQ water.
2.6. Cryo-TEM Measurements. The cryo-TEM analysis of
PEGylated liposomes and PEGylated archaeosomes was real-
ized by Dr. Olivier LAMBERT at the University of Bordeaux4 Journal of Drug Delivery
(Group “Chimie et Biologie des Membranes et Nano-objets”,
UMR 5248 CNRS).
Each sample (5μL) was deposited on a grid covered
with a carbon ﬁlm having 2μm diameter holes previously
exposed to treatment with UV-ozone. The excess of water
was removed by absorption with ﬁlter paper to form a thin
layer of water suspended inside the holes. This grid was then
plungedquickly(EMCPC,Leica)inliquidethane(−178◦C).
Rapid freezing of the thin layer of liquid water in vitreous ice
(absence of crystals) preserved biological structures. Grids
were then placed in a suitable object carrier for observing the
samples at −170◦C. Observation under a microscope (FEI
Tecna F20) was carried out in the mode low dose, limiting
the eﬀects of beam irradiation on the lipid material. Images
were recorded using an ultrasensitive camera (Gatan, USC
1000) 2K∗2K with pixel size of 14μm. The electron dose
used was 10–20 electrons/˚ A2. The image resolution under
these conditions was about 2nm.
2.7. Lipid Composition of Liposomes and Archaeosomes by
HPTLC. The lipid compositions of formulations were deter-
minedafterultraﬁltration.Thesampleswereﬁlteredthrough
10000NMWLporeﬁlters(MicronYM-10,MilliporeCorpo-
ration) by ultracentrifugation at 15 000g for 1 hour at 15◦C.
The supernatants were recovered, lyophilized, dissolved in
1mL of methanol, and analyzed by HPTLC using the auto-
matedHPTLCsystemfromCAMAG(Muttenz,Switzerland).
The samples, the appropriate lipid standard solutions and
a blank solution composed by pure methanol were spotted
on 20 × 10cm HPTLC plates using the Automatic TLC
Sampler 4 from CAMAG (Muttenz, Switzerland). Each lane
was spotted 10mm above the bottom edge of the plate and
was 6mm length with 17mm spacing between lanes. The
spotting volume was 10μLo r2 0μL. A maximum of 20 lanes
wasspottedonasingleplate.Afterevaporationofthesample
solvent, the plates were developed in a closed twin trough
chamber for 20∗10cm plates (CAMAG) containing 10mL
of the mobile phase (CHCl3/MeOH/H2O, 18/4/0.5) in each
trough. The chamber was pre-equilibrated at least 20min
before the development. The development was stopped
when the solvent had migrated 80mm. The plates were
dried on a CAMAG TLC plate heater III at either 60◦C
for 30min. The HPTLC plates were postchromatographic
derivatizated by dipping 5 s into a primuline solution (5mg
of primuline in 100mL of acetone/H2O (80/20) mixture).
HPTLC plates were then dried at room temperature for
10min and at 60◦C for 30min on a CAMAG TLC plate
heater III. Plates were then scanned from 6 mm above
the bottom edge of the plate to the solvent front, using
a CAMAG TLC scanning densitometer. The measurements
were performed in ﬂuorescence mode at λ = 366nm
with a scanning speed of 20mm/s, a slit dimension of
4∗0.2mm (Micro) and deuterium and tungsten lamps. Data
were stored online on a personal computer, and integration
as well as quantiﬁcation was performed with the software
package CATS from CAMAG. Calibration was performed
by applying standard solutions in concentration given
below:
Egg-PC (Rf = 0.04): 10μg, 7.5μg, 5μg, and 2.5μg,
PEG45-DSPE (Rf = 0.46): 2μg, 1μg, 0.5μg, and
0.25μg,
PEG45-Tetraether (Rf = 0.79): 2μg, 1μg, 0.5μg, and
0.25μg.
Peak heights and peak areas were used for quantiﬁcation.
Calibration curves were calculated for each lipid or archaeal
lipid,withalinearregressionmode.Inordertoreduceexper-
imental errors, individual calibration curves were obtained
for every HPTLC plate. The amount of Egg-PC and PEG45-
DSPE in liposomes, after ultraﬁltration, and of Egg-PC and
PEG45-Tetraether in archaeosomes, after ultraﬁltration, were
calculated from the calibration curves.
2.8. Carboxyﬂuorescein Release Proﬁle. CF release proﬁle
from both PEGylated archaeosomes and PEGylated lipo-
somes was measured by ﬂuorescence using a Fluoromax-
3 (Horiba) spectroﬂuorimeter with excitation and emission
wavelengths of 490 and 515nm, respectively. Release was
studied at 4◦Ca n d3 7 ◦C. The ﬂuorescence of both formu-
lations was measured at T0, before (I0) and after (Imax)
Triton-X-100 (2v%) addition (total disruption of liposomial
membranes) and at various times (It) until almost complete
CF release at 4◦Ca n da t3 7 ◦C. Release of the incorporated
dye was calculated using the following equation:
Release (%) =
It −I0
Imax −I0
∗100. (1)
3. Results and Discussion
Archaeosomes made with one or more of the ether lipids
foundinArchaearepresentaninnovativefamilyofliposomes
that demonstrate higher stabilities to several conditions in
comparison with conventional liposomes. The deﬁnition of
archaeosomes also includes the use of synthetically derived
lipids that have the unique structure characteristics of
archaeobacterial ether lipids, that is, regularly branched
phytanyl chains attached via ether bonds at sn-2,3 glycerol
carbons [15]. The lipid membrane of archaeosomes may
be entirely of the bilayer form if made exclusively from
monopolar archaeol (diether) lipids or a monolayer if made
exclusively from bipolar caldarchaeol (tetraether) lipids, or
a combination of monolayers and bilayers if made from
caldarchaeol lipids in addition to archaeol lipids or standard
bilayer-forming phospholipids. The large variety of lipid
structures reﬂects the need for Archaea to adjust their core
lipid structures in order to be able to ensure membrane
functions despite harsh destabilizing environmental condi-
tions (high or low temperatures, high salinity, acidic media,
anaerobic atmosphere, and high pressure) [20].
These atypical characteristics should be particularly
useful for the preparation of highly stable archaeosomes. In
particular, speciﬁc archaeal lipid membrane properties have
to be considered in view to optimize the performance of
archaeosomes: (1) the ether linkages are more stable than
esters over a wide range of pH, and the branching methyl
groups help both to reduce crystallization (membrane lipidsJournal of Drug Delivery 5
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Figure 1: Structure of Egg-PC, PEG45-DSPE, and PEG45-Tetraether.
in the liquid crystalline state at ambient temperature) and
membrane permeability (steric hindrance of the methyl side
groups); (2) the saturated alkyl chains would impart stability
towards oxidative degradation; (3) the unusual stereochem-
istry of the glycerol backbone (opposite to mesophilic organ-
isms) would ensure resistance to attack by phospholipases
released by other organisms; (4) the bipolar lipids span the
membranes and enhance their stability properties and (5)
theadditionofcyclicstructures(inparticularﬁve-membered
rings) in the transmembrane portion of the lipids appears
to be a thermoadaptive response, resulting in enhanced
membrane packing and reduced membrane ﬂuidity.
Consequently, formulations including archaeal lipids
demonstrate relatively higher stabilities to oxidative stress,
high temperature, alkaline or acidic pH, action of phos-
pholipases, bile salts, and serum media. Archaeosomes
can be formed using standard procedures (hydrated ﬁlm
submitted to sonication, extrusion or detergent dialysis) at
any temperature in the physiological range or lower, thus
making it possible to encapsulate thermally labile com-
pounds. Moreover, they can be prepared and stored in the
presence of air/oxygen without any degradation. The in vitro
andinvivostudiesindicatethatarchaeosomesaresafeanddo
not elicit toxicity in mice. Thus, the biocompatibility and the
superior stability properties of archaeosomes in numerous
conditions oﬀer advantages over conventional liposomes in
the manufacture and the use in biotechnology including
vaccine and drug/gene delivery.
However, to study in depth archaeolipid structure-
archaeosome property relationships with a view of optimiz-
ingtheperformanceoftheseunusualliposomesasgene/drug
nanocarriers, suﬃcient amounts of pure natural lipids are
required. Well-deﬁned lipids are diﬃcult to isolate from
natural extracts, and chemical synthesis appears, therefore,
as an attractive means of producing model lipids that
mimic the natural lipids. Within this context, our group
focused on the synthesis and the evaluation of chemically
pure archaeal diether and tetraether lipids that retain some
of the essential structural features of archaeal membrane
lipids.Thesestudiesclearlyshowedtheinterestindeveloping
archaeosome technology from synthetic tetraether lipids
possessing neutral, zwitterionic, or cationic polar heads
groupsforinvitroandinvivo deliveryapplicationsofnucleic
acids and drugs [13, 16–18].
In order to propose a stealth version of synthetic
archaeosomesthatcouldincreasebloodcirculationlongevity
by reducing or preventing protein binding and/or by
inhibiting cell binding/uptake, an additional archaeosome
formulation based on a novel synthetic tetraether lipid was
developed. These stealth archaeosomes could be suitable
for the encapsulation and the in vivo delivery of various
bioactive molecules including peptides which are known to
be highly sensitive to enzymatic or chemical degradations.
Comparative studies in terms of drug-encapsulation eﬃcacy
and formulation stability between standard PEGylated lipo-
somes and PEGylated archaeosomes were then investigated
by following the leakage of the encapsulated aqueous dye
5(6)-carboxyﬂuorescein as a marker.
For that purpose, an archaeosome formulation com-
posed by 90wt% of a classical lipid, Egg-PC, and 10wt%
of a PEGylated tetraether archaeal lipid, PEG45-Tetraether
(Figure 1) was selected. Indeed, previous studies relative to6 Journal of Drug Delivery
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Scheme 1: Synthesis of PEG45-Tetraether lipid.
the use of archaeosomes as gene nanocarriers showed that
the incorporation of 5wt% to 10wt% of tetraether archaeal
lipids into bilayered vesicles led to the best eﬃcient in vitro
gene transfection properties [16]. In parallel, a classical
liposomal formulation composed by 90wt% of Egg-PC and
10wt% of PEG45-DSPE, was prepared in order to evaluate
the inﬂuence of the tetraether structure on the formulation
properties in terms of stability, drug-encapsulation eﬃ-
ciency, and further on the in vivo formulation eﬃcacy. In the
presentapproach,thevesicleformulationswerestudiedfrom
a fundamental point of view, that is, through DLS and cryo-
TEM measurements (size, polydispersity, and morphology),
HPTLC (lipid composition), and CF release (formulation
stability) in order to assess the potentiality of PEGylated
archaeosomes as in vivo nanocarriers.
3.1. Synthesis of PEG45-Tetraether Lipid. The novel PEGy-
lated archaeal lipid (PEG45-Tetraether) was synthesized
through the functionalization of the tetraether backbone
at one terminal end. The synthesis of this unsymmetrical
PEGylated lipid involved the monoprotection of the starting
tetraether diol 1 [13] followed by the introduction of the
poly(ethylene glycol) chain (Scheme 1). The ﬁrst step was
carried out by an easy monoacetylation of diol 1 with
sodium acetate (1equiv.) and acetic anhydride (3.5equiv.)
to give monoacetate 2 in a 49% yield. Alcohol 2 was
then oxidized in a one-pot two-step procedure under
TEMPO catalysis conditions with NaOCl and NaClO2 as
the oxidizing agents. Fine tuning of the pH during the
reaction led to a clean oxidation of 2 to carboxylic acid
3 in a yield of 90%. With acid 3 in hand, we introducedJournal of Drug Delivery 7
Table 1: Size (cumulant results), polydispersity (Ip), and zeta potential of prepared formulations. (ND = nondetermined).
Formulation Size (nm), (Std Dev) Ip Zeta potential (mV)
Egg-PC/PEG45-DSPE 70 (40) 0.30 −20.0 ± 9
Egg-PC/PEG45-Tetraether 80 (30) 0.26 −13.0 ± 6
CF-encapsulated Egg-PC/PEG45-DSPE 90 (37) 0.21 Nd
CF-encapsulated Egg-PC/PEG45-Tetraether 100 (45) 0.26 Nd
50nm
(a)
50nm
(b)
Figure 2: Cryo-TEM photos of (a) Egg-PC/PEG45-Tetraether (90:10wt%) archaeosomes and (b) Egg-PC/PEG45-DSPE (90:10wt%)
liposomes. Bar is 50nm.
a 45-unit PEG chain using commercially available H2N-
PEG45-OMe 4. After optimization of the coupling reaction
conditions, the use of the uronium salt (O-(benzotriazol-
1-yl)1,1,3,3-tetramethyluronium tetraﬂuoroborate (TBTU)/
N,N -diisopropylethylamine (DIEA) system furnished the
expected PEGylated tetraether (80% yield) in addition to
the starting H2N-PEG45-OMe chain (ratio: 80:20). It is
noteworthy that the puriﬁcation of the crude reaction
mixture on a Sephadex LH-20 column allowed the total
removal of the starting carboxylic acid 3. The ﬁnal dea-
cylation of the hydroxyl group under Zempl` en conditions
(MeONa, MeOH) gave the targeted PEG45-Tetraether lipid
in a quantitative yield.
3.2. Physicochemical Characteristics of PEGylated Archaeo-
somes and PEGylated Liposomes. As described in the exper-
imental part, formulations have been prepared using the
classical lipid ﬁlm hydration method followed by vesicle size
reduction under sonication. The mean particle size and zeta
potential of archaeosomes and liposomes were measured
by dynamic light scattering. Particle mean diameters and
polydispersity index are gathered in Table 1 and show that
both liposomes and archaeosomes are similar in size, lower
than 100nm, with a quite narrow dispersity (around 0.30).
In the same way, the mean surface potential of archaeosomes
andliposomeswerecomparablewithslightlynegativevalues.
T h e s er e s u l t sa r ei ng o o da g r e e m e n tw i t hs e v e r a lr e p o r t s
[21, 22] that pointed out the impact of the PEG chains on
liposomal size decrease and on zeta potential values close to
neutrality. Most importantly, these studies revealed that the
atypical structure of the tetraether did not modify the main
characteristics of the resulting PEG-grafted vesicle structures
(shape, size).
Cryo-TEM was employed to investigate the morphology
of the vesicles composed of PEGylated lipids. The images
in Figure 2 show that PEG-bearing archaeosomes were
dispersed and spherical as for classical PEGylated liposomes.
The presence of an external dark circle evidenced the
lipid layer surrounding the internal aqueous volume of the
vesicles. It is noteworthy that no phase segregation has been
evidenced meaning that the prepared formulations are quite
homogenous. The sizes of the vesicles were under 100nm
and the diameter was comprised between 20 to 100nm,
which was in relatively good agreement with data obtained
by DLS. Indeed, DLS measurements gave average diameters
(cumulant results) lower than 100 nm with objects having
diameters ranging from around 20nm to around 200nm.
Besides these characteristics, it is of great interest to
determine the lipid composition after formulation. For
that purpose, we have used an innovative method based
on quantitative thin layer chromatography, named high8 Journal of Drug Delivery
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Figure 3: HPTLC measurements: (a) Scan of a plate at 366nm (ﬂuorescence mode); (b and c) standard curves, based on peak height, for
each lipid composing the prepared liposomes and archaeosomes. (AU = arbitrary unit).
performance thin-layer chromatography (HPTLC). The
HPTLC is a qualitative and quantitative analytical method
allowing obtaining reproducible and reliable results [23].
This method is used, since several years, for analysis and
quantiﬁcation of lipids extracted from various sources [23–
29]. More recently, the use of HPTLC has been developed
for the determination of lipid compositions of liposomes
[30–34] and for peptide analysis in liposomes [35]. We
have, therefore, studied possibilities to use HPTLC for the
determinationoflipidcompositionsofthestudiedliposomes
and archaeosomes. We have found conditions, described
in experimental part, which allowed us to measure lipid
composition. After removal of nonaggregated lipids, the
supernatants were lyophilized and solubilized in methanol in
order to disrupt the nanostructure leading to the recovering
of nonaggregated lipids which can be further analyzedJournal of Drug Delivery 9
Table 2: Amounts of lipids contained in liposomes and archaeosomes calculated from HPTLC data. The given values are an average between
peak height and peak area values. The values are reported to a volume of 1mL.
Liposome formulations Archaeosome formulations
Egg-PC Initial amount (μg) 0.900 (90wt%) 0.900 (90wt%)
Amount in formulation (μg) 0.614 (88wt%) 0.589 (86wt%)
PEG45-DSPE Initial amount (μg) 0.100 (10wt%) —
Amount in formulation (μg) 0.087 (12wt%) —
PEG45-Tetraether Initial amount (μg) — 0.100 (10wt%)
Amount in formulation (μg) — 0.096 (14wt%)
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Figure 4: Release (%) of CF from Egg-PC/PEG45-Tetraether (90:10wt%) archaeosomes and from Egg-PC/PEG45-DSPE (90:10wt%)
liposomes at (a) 4◦C and (b) 37◦C.
by HPTLC as described in the experimental part. It is
worth to note that no peak has been observed on the lane
corresponding to the blank solution. Such result allowed us
to conclude that peaks corresponding to the analyzed lipids
(Egg-PC: Rf = 0.04, PEG45-DSPE: Rf = 0.46 and PEG45-
Tetraether: Rf = 0.79) were not overestimated because of
the presence of other peaks having similar Rf values (Figure
3(a)). Calibration curves, based on either peak height or
peak area, were plotted for each lipid (Figures 3(b) and
3(c)). From these calibration curves, amounts of lipids
containedineachformulationstudiedwerecalculated(Table
2) and compared to initial amount of lipids used to prepare
liposomes and archaeosomes (Table 2). Results given in
Table 2 demonstrated that lipid composition of the prepared
liposomes and archaeosomes are very similar to the initial
lipid compositions: 88/12wt% for Egg-PC/PEG45-DSPE
liposomes instead of an initial composition of 90/10wt%
and 86/14wt% for Egg-PC/PEG45-Tetraether archaeosomes
instead of an initial composition of 90/10wt%.
3.3. Carboxyﬂuorescein Encapsulation and Release Proﬁle.
To assess vesicle stability, the kinetics of encapsulated CF
release from PEG-bearing liposomes and archaeosomes was
studied at 4◦C (standard storage temperature of liposomal
formulations)and37◦C(humanphysiologicaltemperature).
The percent release of CF was calculated from the formula
described in the experimental part after evaluating the
initial amount of encapsulated CF. Thus, a part of the
sample containing the vesicle dispersion was treated with
triton X-100 [36] for lipid membrane disruption. Then,
the ﬂuorescence analysis of the resulting sample allowed
us to determine the CF concentration initially entrapped
in the nanocarrier using a calibration curve beforehand
established.
The release proﬁle of CF from vesicles at 4◦C( Figure
4(a)) showed diﬀerent rates of leakage between liposome
and archaeosome formulations. Indeed, 45% CF release was
found to be approximately 20h for the liposome sample and
100h for the archaeosome sample. This diﬀerent behavior
was dramatically increased when the formulations were
studied at 37◦C. As shown in Figure 4(b), there was a rapid
leakage of CF from conventional liposomes, where almost
70% of the encapsulated marker was lost within 3 hours.
On the contrary, a signiﬁcant improvement in stability was
noted with archaeosomes, which released only 20% during
the same period.
Despite their apparent identical characteristics in terms
of morphology and surface potential, PEGylated liposomes
and archaeosomes exhibited diﬀerent vesicle stabilities. The
presence of only 10wt% of archaeal tetraether lipid in the
liposomal formulations increased signiﬁcantly the nano-
objectstability andallowed aslow releaseof theencapsulated10 Journal of Drug Delivery
dye at 37◦C. This enhanced stability could result from
the membrane spanning organization of the PEGylated
tetraether lipids within the Egg-PC bilayer membrane,
forming a monolayer as previously shown with synthetic
cationic tetraethers [13].
4. Conclusions
In conclusion, we have demonstrated that small proportions
of a novel synthetic PEGylated archaeolipid added to a
liposomal formulation increase signiﬁcantly the nanovector
stability and slow down the constant dye release at 37◦C.
This result is quite promising in so far as a similar behavior
could be expected for invivoapplications.Thisstudyhasalso
shown that HPTLC is a powerful method for analyzing lipid
composition. Following such a fundamental work, we have
recently evaluated the encapsulation of a therapeutic peptide
(anticancer)extractedfrommarineresourcesintoPEGylated
archaeosomes and the in vivo eﬃciency of this peptide-
loaded formulation. The ﬁrst results are very promising and
will be published elsewhere.
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